Russian Bioregulators (overview)
A family of short (2-4 amino acid) peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology. Tissue-specific organ-support peptides: Cartalax, Cardiogen, Cortagen, Chonluten, Livagen, Ovagen, Pancragen, Prostamax, Testagen, Thymogen, Thymulin, Vesugen, Vesilute, Vilon, Bronchogen (Broncogen). Limited Western clinical data.
Russian Bioregulators (overview): A family of short (2-4 amino acid) peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology. Tissue-specific organ-support peptides: Cartalax, Cardiogen, Cortagen, Chonluten, Livagen, Ovagen, Pancragen, Prostamax, Testagen, Thymogen, Thymulin, Vesugen, Vesilute, Vilon, Bronchogen (Broncogen). Limited Western clinical data. The Russian Bioregulators are a family of very short peptides (2-4 amino acids each) developed at the St.
The Russian Bioregulators are a family of very short peptides (2-4 amino acids each) developed at the St. Petersburg Institute of Bioregulation. Each targets a specific organ, Bronchogen for lungs, Cardiogen for heart, Thymalin for immune, etc. Limited Western clinical data, most evidence is Russian. Run as 10-20 day pulses, not continuously.
Most are very short naturally occurring peptide sequences. Federations don't address them specifically.
Used in Russian clinical settings. Not available by US prescription.
Who it's for
- →Users running organ-specific longevity protocols
- →Curious researchers exploring the Khavinson family
- →Anyone running Epitalon or Pinealon already
What to expect
- Week 1
Effects, if any, are subtle.
- Week 4
Pulse complete.
- Week 8
Off-cycle. Effects long-tail and hard to attribute.
Looking at Russian Bioregulators (overview)? Your next 3 steps
- 1Work out your syringe units
Vial size + BAC water turns into the exact units to draw for Russian Bioregulators (overview).
Open calculator → - 2See what to stack & monitor
The companion supplements and the bloodwork worth tracking on this kind of protocol.
Bloodwork guide → - 3Save it & ask the Coach
A free account gets you Coach questions every day, free; membership saves your stack and makes the Coach stack-aware.
Create free account →
How it works (mechanism)
Family of very short (2-4 amino acid) peptides extracted from organ-specific tissue. Each one is proposed to enter target tissue and influence transcription of organ-specific genes. Mechanistic claims are largely Russian preclinical work.
Dosing protocol
Stacks well with
Side effects
When NOT to use
- ⚠Pregnancy / nursing
- ⚠Active malignancy, limited data
Common mistakes
- • Running them continuously instead of pulsing
- • Stacking 5+ different bioregulators expecting compounding effect
- • Crediting Russian-language claims without Western trial replication
What it actually is
This is an overview entry rather than a single compound. The Russian bioregulators are a family of very short peptides — two to four amino acids — developed at the St Petersburg Institute of Bioregulation and Gerontology, each named for the organ it was derived from and is meant to support: Cardiogen for heart, Prostamax for prostate, Thymogen for thymus, Livagen for liver, and a dozen more. Three different things get grouped under the label — organ-extract mixtures such as Thymalin and Epithalamin, synthetic short peptides such as Thymogen, and supplement-marketed cytogen products — and they do not share a regulatory status. What they do share is a single research lineage and a single decisive limitation.
The founding hypothesis is that short peptides derived from an organ can enter cells of that same organ, bind regulatory regions of DNA, and normalise expression of tissue-specific genes — restoring function that has drifted with age. There is published work on peptide regulation of cell differentiation and on delivery. The hypothesis is coherent and it is genuinely unusual: nothing in mainstream pharmacology proposes tissue targeting by sequence origin alone, and nothing outside this tradition has confirmed it.
Forms, and which is which
Each is run in 10 to 20 day pulses, one or two courses a year. Research-chemical supply outside Russia.
Verdict: The traditional protocol, unregulated supply.
Sold for several of the family on the argument that very short peptides survive digestion. Absorption of an intact bioactive dose is not demonstrated.
Verdict: Convenient, unproven.
Whole-tissue extracts rather than defined short peptides, from the same tradition.
Verdict: Cruder mixtures with the same evidence problem.
Epitalon and pinealon have enough published work to warrant separate entries. Most of the rest do not.
Verdict: Where the family's evidence is concentrated.
What it is claimed to do, graded
There is published work on this, including a 2020 paper on peptide regulation of cell differentiation. Model-system evidence, from within the originating tradition.
The core claim of the whole family. Fifteen human-trial records are indexed across the entire group, essentially all from one connected research lineage without independent replication.
The foundational hypothesis, and it has never been independently confirmed. If it were established it would be a significant finding in pharmacology, and it is not treated as one outside this tradition.
Claimed across the family, with long-term human reports from the originating institute. No independent group has replicated them, which is the whole problem — this is not an absence of claimed evidence, it is an absence of anyone else finding it.
Decades of reported use with a benign side-effect profile, and essentially no formal safety study. Well tolerated is not the same as studied.
Grades describe how much human evidence exists for that specific claim, not whether it will work for you or whether it is safe.
Pros and cons
- • Decades of clinical use in Russia with a reported benign safety record
- • Short pulsed courses rather than continuous dosing
- • The underlying hypothesis is at least coherent and specific enough to be testable
- • Inexpensive
- • The entire evidence base traces to one institute and its collaborators, with no independent replication
- • The foundational claim — tissue specificity by sequence origin — has never been confirmed outside that tradition
- • Regulatory status varies by product and country, and none is FDA-approved
- • Effects are invisible and unmeasurable, so there is no way to tell if anything happened
- • The number of organ-specific variants outpaces the evidence for any of them
When to stop
- • Any new cancer diagnosis
- • Any autoimmune symptom appearing or worsening, especially on the thymic members
- • Injection-site reaction that spreads
- • You are running several at once and have no way to attribute anything
Interactions
Compounds proposed to alter gene expression in a body with a tumour are unstudied in either direction.
The thymus-derived members of the family modulate immune function, which is a real caution here.
Stacking several at once is the normal practice in this tradition and makes any effect entirely unattributable.
Taking an organ-targeted peptide alongside treatment for that organ has no interaction data at all.
There is essentially no human interaction literature for this family.
Is this for you?
- • People who find the hypothesis interesting and understand that no independent group has confirmed its central claim
- • Anyone running one at a time, in pulses, rather than a stack
- • You have active cancer
- • You have an autoimmune disease and are considering a thymic member
- • You are pregnant or nursing
- • You want evidence that replicates outside its institute of origin
The one number
Sources for the claims above
- Peptide regulation of cell differentiation
- Peptide bioregulators, delivery and efficacy
- Overview of the bioregulator field
New to Russian Bioregulators (overview)? Grab the starter checklist.
Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.
Numbers redacted in this preview. Members get the full answer, on their own stack.
Ask the Coach anything about Russian Bioregulators (overview) or your own stack. This is it working.
Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.
Unlock the full Coach, from $4.99/week →Frequently asked
What is Russian Bioregulators (overview)?+
Is Russian Bioregulators (overview) FDA approved?+
Is Russian Bioregulators (overview) legal?+
Is Russian Bioregulators (overview) banned by WADA?+
Are you still natty after taking Russian Bioregulators (overview)?+
Do doctors prescribe Russian Bioregulators (overview)?+
What's the typical dose of Russian Bioregulators (overview)?+
What are the side effects of Russian Bioregulators (overview)?+
How long until Russian Bioregulators (overview) starts working?+
What can you stack with Russian Bioregulators (overview)?+
Where do people get Russian Bioregulators (overview)?+
Common questions about Russian Bioregulators (overview)
Tracked alongside Russian Bioregulators (overview)
Same goal, different aisle — each graded on its own evidence in the Pepdex catalog.
More in Longevity
Studied as an anti-aging and sleep-cycle peptide. A tetrapeptide derived from epithalamin, looked at for telomerase activation and circadian / pineal support, with limited human data.
Aimed at brain aging and your body clock. A Russian-origin tripeptide (Glu-Asp-Arg) with limited human data, so treat it as experimental.
A compound studied for protecting the brain and keeping cells alive and insulin-sensitive as you age. A mitochondrial-derived peptide encoded inside mitochondrial DNA, studied for neuroprotection, insulin sensitivity, and cellular survival.
FOXO4 dominant-negative interfering peptide. Selectively triggers apoptosis in senescent cells by disrupting FOXO4-p53 interaction. Animal-model senolytic with strong age-reversal data in mice.